Press Release No. 006/ KFCP-DIR/PR/II/18
Cikarang, 27 February 2018 – PT Kalbe Farma Tbk (Kalbe) today through its subsidiary, PT Kalbio Global Medika (KGM) inaugurated a drugs ingredients and biological products factory that is located in Cikarang. The inauguration of the factory was conducted by the President of Indonesia, Ir. H. Joko Widodo accompanied by the Ministry of Health of Indonesia, Prof. dr. Nila Djuwita F. Moeloek, Sp. M; Minister of Industry, Ir. Airlangga Hartarto, MBA, MMT.; and the Chairman of the Food and Drugs Monitoring Body, Ir. Penny K. Lukito, MCP; as well as the President Director of PT Kalbe Farma Tbk, Vidjongtius. The drug ingredients and biological product factory has obtained the certificate of Good Active Drug Ingredients Manufacturing Methods (CPBBAOB) and Good Drug Manufacturing Methods (CPOB) from the Food and Drugs Monitoring Body (BPOM) and its products are ready to be marketed by the end of 2018.
“The inauguration of this drug ingredients and biological product factory is the form of Kalbe's commitment to take initiative and encourage the creation of integrated pharmaceutical industry, specifically in the form of ingredients independence, mastery of technology, and an increase of exports," said Vidjongtius, President Director of PT Kalbe Farma Tbk. “We hope Kalbe can provide larger contributions for the availability of quality drugs and healthcare products in order to improve the health of the Indonesian people," Vidjongtius continued.
The total early investment of KGM, PT Kalbio Global Medika (KGM) is at Rp. 500 billion to construct the production facility, and allocation of Rp. 200 billion for research and development, as well as technological transfer from China and South Korea.
KGM will manufacture Erythropoietin (EPO) product that is crucial in dialysis and cancer medication. The product is geared to fulfill the domestic needs and is planned to be exported for the ASEAN market and a number of other countries. Aside of Erythropoietin, KGM will also produce Granulocyte Colony Stimulating Factor (GCSF), a medication to increase the production of granulocyte and product with a new molecule, Efepoietin (Long Acting EPO) which shall function to stimulate the forming of the red blood cells. Furthermore it is planned to produce insulin and a number of MAb (Monoclonal Antibody) products for cancer medication.
“In the operations of the drug ingredients and biological product factory, Kalbe is also preparing manpower who are competent in the fields of biotechnology and genetic engineering that is needed to develop and produce the biological product through a collaboration with I3L (Indonesia International Institute for Life Science). This is also a part of Kalbe's efforts in developing Indonesian manpower to have more competencies in the healthcare fields," Vidjongtius continued.
PT Kalbio Global Medika has the facility that produces biological drugs (biosimilar and bio-better) that is located at Delta Silicon Cikarang Industrial Estate on an area of 11,000 sqm. The factory has the advantage of most updated technological facilities, quality system and international-standard facilities, as well as its eco-friendliness.
In 2017, KGM obtained a number of distinguished awards, among which are Facility of the Year Award (FOYA) for Honorable Mentions category that was given by the International Society for Pharmaceutical Engineering. As well as crowned as "The most promising new biologics facility" by IMAPAC, an organization to help businesses around the world in producing a tangible growth as well as increasing the awareness of their social impact on society.
Kalbe at a glance
PT Kalbe Farma Tbk (“Kalbe”) was established in 1966 and is one of the biggest public pharmaceutical companies in Southeast Asia. Kalbe has four main divisions that handle reliable and varied brand portfolio; prescription medicines (Cefspan, Brainact, Broadced, etc); over-the-counter medication division (Woods, Promag, Mixagrip, Komix, Fatigon, etc); health drinks (Hydro Coco, Extra Joss, Nitros); nutrition division (ChilKid, Prenagen, Diabetasol, etc); and distribution division. Kalbe currently has more than 20 subsidiaries, 14 production facilities with international standard, and employs more than 17,000 employees dispersed across more than 71 branches throughout Indonesia.. From 1991, Kalbe is listed at Indonesia Stock Exchange (IDX: KLBF).